Dear Editor,
We are writing in reference to the Educational Review article by Trachtman et al. entitled BRecurrent focal segmental glomerulosclerosis after kidney transplantation^, recently published in the October 2015 issue of Pediatric Nephrology [1] . The text referencing our cited article [2] is erroneous. It states BStraatmann et al. [2] documented that plasmapheresis without concomitant use of immunosuppressive drugs was effective in treating seven out of 29 patients with FSGS who received a kidney transplant and who developed recurrent disease.^This wording suggests that only 7/29 patients had a successful course with plasmapheresis; however, we had a 100 % success rate in 7/7 patients. We performed retrospective chart review on 24 patients who received transplants for FSGS from 1995 to 2013. Among those 24 patients (not 29 as stated), 7 had FSGS recurrence (29 %.) Our early and intensive use of plasmapheresis to treat recurrent FSGS was universally successful, and 7/7 patients have had a complete and sustained remission with a mean follow-up period of 4.5 years. We published our results with plasmapheresis in an unselected, consecutive, strictly pediatric cohort of patients with biopsy-proven recurrent disease. We started plasmapheresis promptly, and some patients did require prolonged plasmapheresis courses (up to 6 months), with the duration guided by the urine protein to creatinine ratio. No additional immunosuppression was used in 4 of the 7 treated patients. We feel that our study provides convincing and timely evidence for prompt and potentially prolonged use of plasmapheresis as a successful treatment for recurrent FSGS.
